IBM is in the pipeline. Obviously they have deep pockets.
-
-
They're also being helped out by NHGRI grants, although I'm sure that money doesn't go all that far in developing a new technology and instrument to run it:Originally posted by NextGenSeq View Post
"The firm is one of several companies or researchers that have been awarded at least $5.7 million from the National Human Genome Research Institute this year to support their efforts in developing technologies for sequencing a human genome at low cost."
http://www.genomeweb.com//node/92521...1&v=6b1f3d4880 -
3rd article, guess they were stealth for quite a while. Competition is good. Hope they give PacBio a run for the money (thanks forum sponsors!)
Comment
-
The more skeptical amongst you might have noticed that this press release (containing few/no details beyond previous, very old announcements) came out at a similar time to the announcement of the Justice department's anti-trust probe into IBM...Last edited by 454newbie; 03-08-2011, 10:28 AM.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment